Literature DB >> 30603489

Endothelial Progenitor Cells' Classification and Application in Neurological Diseases.

Jing-Jing Yuan1,2, Jing Yang1, Shi-Lei Sun1, Rui Zhang1, Yu-Ming Xu1.   

Abstract

The therapeutic effects of endothelial progenitor cells (EPCs) on ischemic stroke have been extensively studied in recent years. However, the differences in early EPCs and endothelial outgrowth cells (EOCs) are still unclear. Clarifications of their respective properties and specific functioning characteristics contribute to better applications of EPCs in ischemic diseases. In this review, we discuss cellular origin, isolation, culture, surface markers of early EPCs and EOCs and relevant applications in neurological diseases. We conclude that EOCs possess all characteristics of true endothelial progenitors and have potent advantages in EPC-based therapies for ischemic diseases. A number of preclinical and clinical applications of EPCs in neurological diseases are under study. More studies are needed to determine the specific characteristics of EPCs and the relevant mechanisms of EPCs for neurological diseases.

Entities:  

Keywords:  Cell origin; Early endothelial progenitor cells; Endothelial outgrowth cells; Neurological disease; Surface antigen expression

Year:  2017        PMID: 30603489      PMCID: PMC6171603          DOI: 10.1007/s13770-017-0043-4

Source DB:  PubMed          Journal:  Tissue Eng Regen Med        ISSN: 1738-2696            Impact factor:   4.169


  2 in total

1.  Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis.

Authors:  Filipa Lopes-Coelho; Fernanda Silva; Sofia Gouveia-Fernandes; Carmo Martins; Nuno Lopes; Germana Domingues; Catarina Brito; António M Almeida; Sofia A Pereira; Jacinta Serpa
Journal:  Cells       Date:  2020-01-01       Impact factor: 6.600

2.  MicroRNA-126 and VEGF enhance the function of endothelial progenitor cells in acute myocardial infarction.

Authors:  Ying Zhang; Yi Xu; Ke Zhou; Guoying Kao; Jun Xiao
Journal:  Exp Ther Med       Date:  2021-12-14       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.